Drug intelligence / Profile preview

chidamide + azacitidine

Development stage
Phase 2
Modality
Small Molecules
Administration
Oral, Subcutaneous, Intravenous
01

Overview

Chidamide + azacitidine is a combination epigenetic therapy that pairs a histone deacetylase inhibitor (chidamide) with a DNA methyltransferase inhibitor (azacitidine). This dual epigenetic regulating treatment shows synergistic effects in treating hematological malignancies. Chidamide specifically targets HDAC1, 2, 3, and 10, preventing histone deacetylation and promoting gene expression. Azacitidine works through cytotoxicity (incorporating into RNA/DNA) and hypomethylation (inhibiting DNA methyltransferase). The combination has shown particular efficacy in peripheral T-cell lymphomas, especially angioimmunoblastic T-cell lymphoma (AITL), and is being investigated for acute myeloid leukemia and other hematological cancers.

Brand names
Vidaza (azacitidine)Onureg (azacitidine)Epidaza (chidamide)
Other names
5-azacytidine (azacitidine)HBI-8000 (chidamide)
02

Targets

DNMT1 (DNA (cytosine-5)-methyltransferase 1)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)

Beyond the preview

Go deeper on chidamide + azacitidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chidamide + azacitidine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call